person · Reporting owner

MAIDA ANTHONY E III

Disclosed activity across 5 companies

Tapewire entity: 30643
SEC CIK: 0001273213

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ONCOSEC MEDICAL IncONCS · Entity 117092	Director	March 29, 2017	April 03, 2017
Oncotelic Therapeutics, Inc.OTLC · Entity 7822	Director · DIRECTOR AND CMO - TRANS. MED.	July 10, 2026	July 14, 2026
RANGE IMPACT, INC.VBIO · Entity 6807	Director	May 08, 2019	May 14, 2019
SPECTRUM PHARMACEUTICALS INCSPPI · Entity 111009	Director	May 29, 2019	May 31, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ONCOSEC MEDICAL Inc

Report date March 29, 2017 · Filed April 03, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2027-03-29	Direct	131,500	Reported balance After 2017-03-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-03-29 · Grant · Acquired 20,000 · Balance 131,500 F1: Vesting in 12 equal monthly increments, with the first 1/12th vesting on the first monthly anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting in 12 equal monthly increments, with the first 1/12th vesting on the first monthly anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.

Oncotelic Therapeutics, Inc.

Report date July 10, 2026 · Filed July 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	1,500	Reported balance After 2026-07-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-10 · Grant · Acquired 1,500 · Balance 1,500 F1: On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share. F2: The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

Filing footnotes · ownership attribution and instrument terms

F1: On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

F2: The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

RANGE IMPACT, INC.

Report date May 08, 2019 · Filed May 14, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2029-05-08	Direct	612,559	Reported balance After 2019-05-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-05-08 · Grant · Acquired 500,000 · Balance 612,559 F1: Subject to the Reporting Person's continuous service to the Corporation, 1/2 of the shares subject to the option vest upon shareholder approval of an increase in shares of common stock available for issuance under the Corporation's 2012 Stock Incentive Plan and 1/2 of the shares will vest 12 months after that date. In the event of death of the Reporting Person, all shares subject to the Option Grant will vest 100%.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to the Reporting Person's continuous service to the Corporation, 1/2 of the shares subject to the option vest upon shareholder approval of an increase in shares of common stock available for issuance under the Corporation's 2012 Stock Incentive Plan and 1/2 of the shares will vest 12 months after that date. In the event of death of the Reporting Person, all shares subject to the Option Grant will vest 100%.

SPECTRUM PHARMACEUTICALS INC

Report date May 29, 2019 · Filed May 31, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	Direct	29,607	Ending reported balance After 2019-05-29 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-05-29 · Exercise / conversion · Acquired 50,000 · Balance 72,250 Row 2 · 2019-05-29 · Sale · Disposed 42,643 · Balance 29,607 F1: This transaction represents an open market sale of a portion of the expiring stock options exercised on this Form 4 to satisfy the Reporting Person's payment of the exercise price and the taxes associated with such exercise. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.695 to $7.82, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Stock Option Exercise (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09 · Expires 2019-06-26	Direct	0	Reported balance After 2019-05-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-05-29 · Exercise / conversion · Disposed 50,000 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F1: This transaction represents an open market sale of a portion of the expiring stock options exercised on this Form 4 to satisfy the Reporting Person's payment of the exercise price and the taxes associated with such exercise.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.695 to $7.82, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

9 METERS BIOPHARMA, INC.

Report date April 24, 2020 · Filed May 04, 2020

Section 16 reporting ended · disclosed 2020-05-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2030-04-24	Direct	25,000	Reported balance After 2020-04-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-04-24 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vested in full on the grant date, 4/24/2020.

Filing footnotes · ownership attribution and instrument terms

F1: This option vested in full on the grant date, 4/24/2020.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 10, 2026 Filed Jul 14, 2026 20:00 UTC	Oncotelic Therapeutics, Inc. OTLC · Entity 7822	GrantRestricted stock Units · Derivative	1,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001493152-26-033169 · ownership.xml · derivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director · DIRECTOR AND CMO - TRANS. MED. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Series A Preferred Stock · 1,500 shares Expires not disclosed F1 · security: On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share. F2 · derivative.exercise_date: The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting. F2 · derivative.expiration_date: The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting. Read SEC document
September 03, 2021 Filed Sep 8, 2021 21:00 UTC	Oncotelic Therapeutics, Inc. OTLC · Entity 7822	GrantStock Options · Derivative	600,000	$0.00 Strike: $0.14	$0.00	Disclosure SEC source: 0001493152-21-022219 · ownership.xml · derivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director · Chief Clin. Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2031-09-03 F1 · derivative.exercise_date: Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022. Read SEC document
July 08, 2021 Filed Jul 16, 2021 21:39 UTC	Oncotelic Therapeutics, Inc. OTLC · Entity 7822	GrantStock Options · Derivative	400,000	$0.00 Strike: $0.16	$0.00	Disclosure SEC source: 0001493152-21-017107 · ownership.xml · derivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director · CHIEF CLINICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-07-08 F3 · shares: Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant. Read SEC document
March 31, 2021 Filed Jul 16, 2021 21:39 UTC	Oncotelic Therapeutics, Inc. OTLC · Entity 7822	ConversionSeries A Convertible Preferred Stock · Derivative	938	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-21-017107 · ownership.xml · derivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director · CHIEF CLINICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 938,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer. F1 · price: Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer. F2 · derivative.expiration_date: Shares of the Series A Convertible Preferred Stock does not expire. Read SEC document
March 31, 2021 Filed Jul 16, 2021 21:39 UTC	Oncotelic Therapeutics, Inc. OTLC · Entity 7822	ConversionCommon Stock	938,646	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-21-017107 · ownership.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director · CHIEF CLINICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer. Read SEC document
April 24, 2020 Filed May 4, 2020 21:55 UTC	9 METERS BIOPHARMA, INC. NMTR · Entity 114271	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $0.60	$0.00	Disclosure SEC source: 0001551986-20-000106 · wf-form4_158862932359777.xml · derivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2030-04-24 F1 · derivative.exercise_date: This option vested in full on the grant date, 4/24/2020. Read SEC document
May 31, 2019 Filed Jun 4, 2019 23:24 UTC	9 METERS BIOPHARMA, INC. INNT · Entity 114271	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.28	$0.00	Disclosure SEC source: 0001551986-19-000070 · wf-form4_155969068468241.xml · derivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: Grant to the reporting person of stock options under the Innovate Biopharmaceuticals, Inc. 2012 Omnibus Incentive Plan. These stock options vest in 36 equal monthly installments. Read SEC document
May 29, 2019 Filed May 31, 2019 09:33 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	50,000	$0.00 Strike: $6.09	$0.00	Disclosure SEC source: 0001209191-19-033552 · doc4.xml · derivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 29, 2019 Filed May 31, 2019 09:33 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	42,643	$7.75	$330,355.32	Disclosure SEC source: 0001209191-19-033552 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,607 F1 · kind: This transaction represents an open market sale of a portion of the expiring stock options exercised on this Form 4 to satisfy the Reporting Person's payment of the exercise price and the taxes associated with such exercise. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.695 to $7.82, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
May 29, 2019 Filed May 31, 2019 09:33 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	50,000	$6.09	$304,500.00	Disclosure SEC source: 0001209191-19-033552 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 08, 2019 Filed May 14, 2019 00:01 UTC	RANGE IMPACT, INC. VBIO · Entity 6807	GrantStock Option (Right to Buy) · Derivative	500,000	$0.00 Strike: $0.35	$0.00	Disclosure SEC source: 0001493152-19-006973 · ownership.xml · derivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,559 Underlying: Common Stock · 500,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Corporation, 1/2 of the shares subject to the option vest upon shareholder approval of an increase in shares of common stock available for issuance under the Corporation's 2012 Stock Incentive Plan and 1/2 of the shares will vest 12 months after that date. In the event of death of the Reporting Person, all shares subject to the Option Grant will vest 100%. Read SEC document
April 11, 2019 Filed Apr 12, 2019 18:01 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	10,738	$10.67	$114,574.46	Disclosure SEC source: 0001209191-19-024510 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,250 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. Read SEC document
March 21, 2019 Filed Mar 22, 2019 19:54 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	5,500	$0.00 Strike: $5.05	$0.00	Disclosure SEC source: 0001209191-19-021093 · doc4.xml · derivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 5,500 shares Expires 2020-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 21, 2019 Filed Mar 22, 2019 19:54 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	5,500	$10.00	$55,000.00	Disclosure SEC source: 0001209191-19-021093 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,988 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. Read SEC document
March 21, 2019 Filed Mar 22, 2019 19:54 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	5,500	$5.05	$27,775.00	Disclosure SEC source: 0001209191-19-021093 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 21, 2019 Filed Feb 22, 2019 16:31 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	5,500	$0.00 Strike: $5.05	$0.00	Disclosure SEC source: 0001209191-19-012593 · doc4.xml · derivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,800 Underlying: Common Stock · 5,500 shares Expires 2020-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 21, 2019 Filed Feb 22, 2019 16:31 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	5,500	$11.63	$63,965.00	Disclosure SEC source: 0001209191-19-012593 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,988 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. Read SEC document
February 21, 2019 Filed Feb 22, 2019 16:31 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	5,500	$5.05	$27,775.00	Disclosure SEC source: 0001209191-19-012593 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 24, 2019 Filed Jan 25, 2019 21:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	5,700	$0.00 Strike: $5.05	$0.00	Disclosure SEC source: 0001209191-19-005455 · doc4.xml · derivative · entry 6 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,300 Underlying: Common Stock · 5,700 shares Expires 2020-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 24, 2019 Filed Jan 25, 2019 21:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	1,550	$0.00 Strike: $3.92	$0.00	Disclosure SEC source: 0001209191-19-005455 · doc4.xml · derivative · entry 5 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,550 shares Expires 2020-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option, representing the right to purchase a total of 30,000 shares of common stock, was granted on July 1, 2010. The stock option became exercisable as to 7,500 shares on July 1, 2010, 7,500 shares on July 1, 2011, 7,500 shares on July 1, 2012 and 7,500 shares on July 1, 2013. Read SEC document
January 24, 2019 Filed Jan 25, 2019 21:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	5,700	$10.37	$59,109.00	Disclosure SEC source: 0001209191-19-005455 · doc4.xml · nonDerivative · entry 4 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,988 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. Read SEC document
January 24, 2019 Filed Jan 25, 2019 21:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	5,700	$5.05	$28,785.00	Disclosure SEC source: 0001209191-19-005455 · doc4.xml · nonDerivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 24, 2019 Filed Jan 25, 2019 21:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	1,550	$10.37	$16,073.50	Disclosure SEC source: 0001209191-19-005455 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,988 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. Read SEC document
January 24, 2019 Filed Jan 25, 2019 21:27 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	1,550	$3.92	$6,076.00	Disclosure SEC source: 0001209191-19-005455 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 07, 2019 Filed Jan 8, 2019 17:56 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	7,250	$0.00 Strike: $3.92	$0.00	Disclosure SEC source: 0001209191-19-002885 · doc4.xml · derivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550 Underlying: Common Stock · 7,250 shares Expires 2020-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option, representing the right to purchase a total of 30,000 shares of common stock, was granted on July 1, 2010. The stock option became exercisable as to 7,500 shares on July 1, 2010, 7,500 shares on July 1, 2011, 7,500 shares on July 1, 2012 and 7,500 shares on July 1, 2013. Read SEC document
January 07, 2019 Filed Jan 8, 2019 17:56 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	7,250	$10.00	$72,500.00	Disclosure SEC source: 0001209191-19-002885 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,988 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. Read SEC document
January 07, 2019 Filed Jan 8, 2019 17:56 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	7,250	$3.92	$28,420.00	Disclosure SEC source: 0001209191-19-002885 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 06, 2018 Filed Dec 7, 2018 17:26 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	7,250	$0.00 Strike: $3.92	$0.00	Disclosure SEC source: 0001209191-18-061554 · doc4.xml · derivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 7,250 shares Expires 2020-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option, representing the right to purchase a total of 30,000 shares of common stock, was granted on July 1, 2010. The stock option became exercisable as to 7,500 shares on July 1, 2010, 7,500 shares on July 1, 2011, 7,500 shares on July 1, 2012 and 7,500 shares on July 1, 2013. Read SEC document
December 06, 2018 Filed Dec 7, 2018 17:26 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	7,250	$12.60	$91,350.00	Disclosure SEC source: 0001209191-18-061554 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,988 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. Read SEC document
December 06, 2018 Filed Dec 7, 2018 17:26 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	7,250	$3.92	$28,420.00	Disclosure SEC source: 0001209191-18-061554 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 04, 2018 Filed Dec 7, 2018 22:21 UTC	9 METERS BIOPHARMA, INC. INNT · Entity 114271	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $2.41	$0.00	Disclosure SEC source: 0001551986-18-000070 · wf-form4_154422130300003.xml · derivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2028-12-04 F1 · derivative.exercise_date: Grant to the reporting person of stock options under the Innovate Biopharmaceuticals, Inc. 2012 Omnibus Incentive Plan. These stock options vest in 36 equal monthly installments. Read SEC document
November 08, 2018 Filed Nov 9, 2018 18:50 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	7,250	$0.00 Strike: $3.92	$0.00	Disclosure SEC source: 0001209191-18-058024 · doc4.xml · derivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,050 Underlying: Common Stock · 7,250 shares Expires 2020-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option, representing the right to purchase a total of 30,000 shares of common stock, was granted on July 1, 2010. The stock option became exercisable as to 7,500 shares on July 1, 2010, 7,500 shares on July 1, 2011, 7,500 shares on July 1, 2012 and 7,500 shares on July 1, 2013. Read SEC document
November 08, 2018 Filed Nov 9, 2018 18:50 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	SaleCommon Stock, $0.001 par value	7,250	$13.07	$94,757.50	Disclosure SEC source: 0001209191-18-058024 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,988 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018. Read SEC document
November 08, 2018 Filed Nov 9, 2018 18:50 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	7,250	$3.92	$28,420.00	Disclosure SEC source: 0001209191-18-058024 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 18, 2018 Filed Jun 19, 2018 18:46 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $19.95	$0.00	Disclosure SEC source: 0001209191-18-038677 · doc4.xml · derivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-18 F2 · derivative.exercise_date: 25% of the option shares vested on June 18, 2018. The remaining option shares shall vest in 25% equal annual amounts on each anniversary date of the grant over three years. Read SEC document
June 18, 2018 Filed Jun 19, 2018 18:46 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantCommon Stock, $0.001 par value	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-18-038677 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,988 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 18, 2019 or (2) the date of the company's 2019 Annual Meeting of Stockholders. Read SEC document
July 17, 2017 Filed Jul 18, 2017 18:02 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionStock Option Exercise (Right to Buy) · Derivative	15,000	$0.00 Strike: $6.90	$0.00	Disclosure SEC source: 0001209191-17-045562 · doc4.xml · derivative · entry 5 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option, representing the right to purchase a total of 15,000 shares of common stock, was granted on July 20, 2007. The stock option became exercisable as to 3,750 shares on July 20, 2007, 3,750 shares on July 20, 2008, 3,750 shares on July 20, 2009, and 3,750 shares on July 20, 2010. Read SEC document
July 17, 2017 Filed Jul 18, 2017 18:02 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Tax withholdingCommon Stock, $0.001 par value	442	$7.53	$3,328.26	Disclosure SEC source: 0001209191-17-045562 · doc4.xml · nonDerivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,988 F2 · shares: Represents shares withheld by Spectrum to satisfy the Reporting Person's tax withholding obligations. The shares have not been sold by the Reporting Person or by Spectrum. The shares have been cancelled by the transfer agent. Read SEC document
July 17, 2017 Filed Jul 18, 2017 18:02 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Tax withholdingCommon Stock, $0.001 par value	13,745	$7.53	$103,499.85	Disclosure SEC source: 0001209191-17-045562 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,430 F1 · shares: Represents shares withheld by Spectrum to satisfy the Reporting Person's payment of the exercise price. The shares have not been sold by the Reporting Person or by Spectrum. The shares have been cancelled by the transfer agent. Read SEC document
July 17, 2017 Filed Jul 18, 2017 18:02 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Exercise / conversionCommon Stock, $0.001 par value	15,000	$6.90	$103,500.00	Disclosure SEC source: 0001209191-17-045562 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2017 Filed Jun 29, 2017 18:39 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Tax withholdingCommon Stock, $0.001 par value	880	$7.54	$6,635.20	Disclosure SEC source: 0001209191-17-042386 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,175 F1 · shares: Represents shares withheld by Spectrum to satisfy the Reporting Person's tax withholding obligations. The shares have not been sold by the Reporting Person or by Spectrum. The shares have been cancelled by the transfer agent. Read SEC document
June 13, 2017 Filed Jun 15, 2017 16:56 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $6.48	$0.00	Disclosure SEC source: 0001209191-17-040176 · doc4.xml · derivative · entry 4 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-13 F3 · derivative.exercise_date: 25% of the option shares vested on June 13, 2017. The remaining option shares shall vest in 25% equal annual amounts on each anniversary date of the grant over three years. Read SEC document
June 13, 2017 Filed Jun 15, 2017 16:56 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GrantCommon Stock, $0.001 par value	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040176 · doc4.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,055 F2 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 13, 2018 or (2) the date of the company's 2018 Annual Meeting of Shareholders. Read SEC document
June 13, 2017 Filed Jun 15, 2017 16:56 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	Tax withholdingCommon Stock, $0.001 par value	3,523	$6.48	$22,829.04	Disclosure SEC source: 0001209191-17-040176 · doc4.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,055 F1 · shares: Represents shares withheld by Spectrum to satisfy the Reporting Person's tax withholding obligations. The shares have not been sold by the Reporting Person or by Spectrum. The shares have been cancelled by the transfer agent. Read SEC document
March 29, 2017 Filed Apr 3, 2017 06:10 UTC	ONCOSEC MEDICAL Inc ONCS · Entity 117092	GrantOption to Purchase Common Stock · Derivative	20,000	$1.34 Strike: $1.34	$26,800.00	Disclosure SEC source: 0001493152-17-003341 · form4.xml · derivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,500 Underlying: Common Stock · 20,000 shares Expires 2027-03-29 F1 · derivative.exercise_date: Vesting in 12 equal monthly increments, with the first 1/12th vesting on the first monthly anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document
February 17, 2017 Filed Feb 12, 2018 18:22 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GiftCommon Stock, $0.001 Par Value	6,975	$0.00	$0.00	Disclosure SEC source: 0001209191-18-009346 · doc5.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,988 F1 · kind: This transaction involved a gift of securities by the reporting person to his three adult children, who do not share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his three adult children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or any other purpose. Read SEC document
January 15, 2016 Filed Feb 10, 2017 14:49 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GiftCommon Stock, $0.001 Par Value	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-17-009454 · doc5.xml · nonDerivative · entry 3 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daughter Disclosed balance after: 6,192 F2 · kind: This transaction involved a gift of securities by the reporting person to his adult daughter who shares the reporting person's household. The reporting person has an indirect beneficial ownership for purposes of Section 16. The reporting person disclaims beneficial ownership of the shares held by his adult daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or any other purpose. F2 · ownership.nature: This transaction involved a gift of securities by the reporting person to his adult daughter who shares the reporting person's household. The reporting person has an indirect beneficial ownership for purposes of Section 16. The reporting person disclaims beneficial ownership of the shares held by his adult daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or any other purpose. Read SEC document
January 15, 2016 Filed Feb 10, 2017 14:49 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GiftCommon Stock, $0.001 Par Value	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-17-009454 · doc5.xml · nonDerivative · entry 2 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,553 F2 · kind: This transaction involved a gift of securities by the reporting person to his adult daughter who shares the reporting person's household. The reporting person has an indirect beneficial ownership for purposes of Section 16. The reporting person disclaims beneficial ownership of the shares held by his adult daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or any other purpose. Read SEC document
January 15, 2016 Filed Feb 10, 2017 14:49 UTC	SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009	GiftCommon Stock, $0.001 Par Value	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-009454 · doc5.xml · nonDerivative · entry 1 MAIDA ANTHONY E III · CIK 0001273213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,553 F1 · kind: This transaction involved a gift of securities by the reporting person to his two adult children, who do not share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his two adult children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.